GM-CSF in Neuroinflammation: Licensing Myeloid Cells for Tissue Damage

Trends in Immunology

Volumn 36, Issue 10, 2015, Pages 651-662

  Croxford, Andrew L ^a   Spath, Sabine ^a   Becher, Burkhard ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

CNS; GM CSF; Monocytes; MS; Neuroinflammation; Tissue damage

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

BONE MARROW CELL; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL FUNCTION; CYTOKINE PRODUCTION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HELPER CELL; HUMAN; MONOCYTE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; REVIEW; TISSUE INJURY; ANIMAL; CENTRAL NERVOUS SYSTEM DISEASE; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; IMMUNOMODULATION; INFLAMMATION; METABOLISM; PATHOLOGY;

ANIMALS; CELL COMMUNICATION; CELL DIFFERENTIATION; CENTRAL NERVOUS SYSTEM DISEASES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENE EXPRESSION REGULATION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INFLAMMATION; MULTIPLE SCLEROSIS; MYELOID CELLS; NEUROIMMUNOMODULATION; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84942516683     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2015.08.004     Document Type: Review

References (93)

1. Rivers T.M., et al. Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. J. Exp. Med. 1933, 58:39-53.
2. Ben-Nun A., et al. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur. J. Immunol. 1981, 11:195-199.
3. Dyment D.A., et al. Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance. Hum. Mol. Genet. 2005, 14:2019-2026.
4. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476:214-219. The International Multiple Sclerosis Genetics Consortium and the Wellcome Trust Case Control Consortium 2.
5. Siffrin V., et al. In vivo imaging of partially reversible Th17 cell-induced neuronal dysfunction in the course of encephalomyelitis. Immunity 2010, 33:424-436.
6. + T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 2000, 192:393-404.
7. Codarri L., et al. Cytokine networks in multiple sclerosis: lost in translation. Curr. Opin. Neurol. 2010, 23:205-211.
8. Becher B., Segal B.M. Th17 cytokines in autoimmune neuro-inflammation. Curr. Opin. Immunol. 2011, 23:707-712.
9. Korn T., et al. IL-17 and Th17 Cells. Annu. Rev. Immunol. 2009, 27:485-517.
10. Hirota K., et al. Fate mapping of IL-17-producing T cells in inflammatory responses. Nat. Immunol. 2011, 12:255-263.
11. Kurschus F.C., et al. Genetic proof for the transient nature of the Th17 phenotype. Eur. J. Immunol. 2010, 40:3336-3346.
12. Gaffen S.L., et al. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat. Rev. Immunol. 2014, 14:585-600.
13. McAleer J.P., Kolls J.K. Directing traffic: IL-17 and IL-22 coordinate pulmonary immune defense. Immunol. Rev. 2014, 260:129-144.
14. Askenase M.H., et al. Bone-marrow-resident NK cells prime monocytes for regulatory function during infection. Immunity 2015, 42:1130-1142.
15. Shiomi A., Usui T. Pivotal roles of GM-CSF in autoimmunity and inflammation. Mediat. Inflamm. 2015, 2015:568543.
16. Wynn T.A. Type 2 cytokines: mechanisms and therapeutic strategies. Nat. Rev. Immunol. 2015, 15:271-282.
17. McQualter J.L., et al. Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis. J. Exp. Med. 2001, 194:873-882.
18. Codarri L., et al. RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat. Immunol. 2011, 12:560-567.
19. El-Behi M., et al. The encephalitogenicity of Th17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat. Immunol. 2011, 12:568-575.
20. + T cell response. J. Exp. Med. 2013, 210:1603-1619.
21. Lin C.C., et al. Bhlhe40 controls cytokine production by T cells and is essential for pathogenicity in autoimmune neuroinflammation. Nat. Commun. 2014, 5:3551.
22. Sheng W., et al. STAT5 programs a distinct subset of GM-CSF-producing T helper cells that is essential for autoimmune neuroinflammation. Cell Res. 2014, 24:1387-1402.
23. Noster R., et al. IL-17 and GM-CSF expression are antagonistically regulated by human T helper cells. Sci. Transl. Med. 2014, 6:241ra280.
24. Hartmann F.J., et al. Multiple sclerosis-associated IL2RA polymorphism controls GM-CSF production in human Th cells. Nat. Commun. 2014, 5:5056.
25. Greter M., et al. GM-CSF controls nonlymphoid tissue dendritic cell homeostasis but is dispensable for the differentiation of inflammatory dendritic cells. Immunity 2012, 36:1031-1046.
26. Bhattacharya P., et al. GM-CSF: an immune modulatory cytokine that can suppress autoimmunity. Cytokine 2015, Published online June 22, 2015. 10.1016/j.cyto.2015.05.030.
27. Inaba K., et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 1992, 176:1693-1702.
28. + macrophages and dendritic cells. Immunity 2015, 42:1197-1211.
29. Bogunovic M., et al. Origin of the lamina propria dendritic cell network. Immunity 2009, 31:513-525.
30. + dermal dendritic cells play a critical role in Th effector cell differentiation after subcutaneous immunization. J. Exp. Med. 2010, 207:953-961.
31. Kingston D., et al. The concerted action of GM-CSF and Flt3-ligand on in vivo dendritic cell homeostasis. Blood 2009, 114:835-843.
32. Varol C., et al. Intestinal lamina propria dendritic cell subsets have different origin and functions. Immunity 2009, 31:502-512.
33. Griseri T., et al. Granulocyte macrophage colony-stimulating factor-activated eosinophils promote interleukin-23 driven chronic colitis. Immunity 2015, 43:187-199.
34. Wumesh K.C., et al. L-Myc expression by dendritic cells is required for optimal T-cell priming. Nature 2014, 507:243-247.
35. Ko H.J., et al. GM-CSF-responsive monocyte-derived dendritic cells are pivotal in Th17 pathogenesis. J. Immunol. 2014, 192:2202-2209.
36. Kobayashi S.D., et al. Spontaneous neutrophil apoptosis and regulation of cell survival by granulocyte macrophage-colony stimulating factor. J. Leukoc. Biol. 2005, 78:1408-1418.
37. Zhan Y., et al. The inflammatory cytokine, GM-CSF, alters the developmental outcome of murine dendritic cells. Eur. J. Immunol. 2012, 42:2889-2900.
38. Dabritz J., et al. Reprogramming of monocytes by GM-CSF contributes to regulatory immune functions during intestinal inflammation. J. Immunol. 2015, 194:2424-2438.
39. Darrieutort-Laffite C., et al. IL-1beta and TNFalpha promote monocyte viability through the induction of GM-CSF expression by rheumatoid arthritis synovial fibroblasts. Mediat. Inflamm. 2014, 2014:241840.
40. McDermott A.J., et al. Role of GM-CSF in the inflammatory cytokine network that regulates neutrophil influx into the colonic mucosa during Clostridium difficile infection in mice. Gut Microbes 2014, 5:476-484.
41. Kroenke M.A., et al. EAE mediated by a non-IFN-gamma/non-IL-17 pathway. Eur. J. Iimmunol. 2010, 40:2340-2348.
42. Heppner F.L., et al. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat. Med. 2005, 11:146-152.
43. Bruttger J., et al. Genetic cell ablation reveals clusters of local self-renewing microglia in the mammalian central nervous system. Immunity 2015, 43:92-106.
44. Ponomarev E.D., et al. GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis. J. Immunol. 2007, 178:39-48.
45. Wieghofer P., et al. Genetic targeting of microglia. Glia 2015, 63:1-22.
46. Ko H.J., et al. GM-CSF-responsive monocyte-derived dendritic cells are pivotal in Th17 pathogenesis. J. Immunol. 2014, 192:2202-2209.
47. hi monocytes are crucial for the effector phase of autoimmunity in the central nervous system. Brain 2009, 132:2487-2500.
48. Yamasaki R., et al. Differential roles of microglia and monocytes in the inflamed central nervous system. J. Exp. Med. 2014, 211:1533-1549.
49. + monocytes and licenses autoimmunity. Immunity 2015, Published online September 1, 2015. 10.1016/j.immuni.2015.08.010.
50. van de Laar L., et al. Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy. Blood 2012, 119:3383-3393.
51. low/- peripheral dendritic cells are GM-CSF-independent and are not required for Th cell priming after subcutaneous immunization. PLoS ONE 2011, 6:e25660.
52. Baker D., et al. Critical appraisal of animal models of multiple sclerosis. Mult. Scler. 2011, 17:647-657.
53. Tsou C.L., et al. Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J. Clin. Invest. 2007, 117:902-909.
54. Huang D.R., et al. Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. J. Exp. Med. 2001, 193:713-726.
55. Mahad D.J., Ransohoff R.M. The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Semin. Immunol. 2003, 15:23-32.
56. Yamasaki R., et al. Differential roles of microglia and monocytes in the inflamed central nervous system. J. Exp. Med. 2014, 192:2202-2209.
57. Vogel D.Y., et al. Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. J. Neuroinflamm. 2013, 10:35.
58. Gilgun-Sherki Y., et al. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J. Neurol. 2004, 251:261-268.
59. Vladimirova O., et al. The activation of protein kinase C induces higher production of reactive oxygen species by mononuclear cells in patients with multiple sclerosis than in controls. Inflamm. Res. 1999, 412-416.
60. Linker R.A., et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011, 134:678-692.
61. Gold R., et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N. Engl. J. Med. 2012, 367:1098-1107.
62. Opdenakker G., Van Damme J. Probing cytokines, chemokines and matrix metalloproteinases towards better immunotherapies of multiple sclerosis. Cytokine Growth Factor Rev. 2011, 22:359-365.
63. Matsuki T., et al. Abnormal T cell activation caused by the imbalance of the IL-1/IL-1R antagonist system is responsible for the development of experimental autoimmune encephalomyelitis. Int. Immunol. 2006, 18:399-407.
64. Argaw A.T., et al. IL-1beta regulates blood-brain barrier permeability via reactivation of the hypoxia-angiogenesis program. J. Immunol. 2006, 177:5574-5584.
65. Chung Y., et al. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 2009, 30:576-587.
66. + regulatory T cells. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:18460-18465.
67. Sonderegger I., et al. GM-CSF mediates autoimmunity by enhancing IL-6-dependent Th17 cell development and survival. J. Exp. Med. 2008, 205:2281-2294.
68. Kim H.J., et al. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J. Immunol. 2004, 172:7144-7153.
69. Weber B., et al. Left hippocampal pathology is associated with atypical language lateralization in patients with focal epilepsy. Brain 2006, 129:346-351.
70. Comabella M., et al. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain 2009, 132:3353-3365.
71. Paty D.W., Li D.K. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993, 43:662-667.
72. Polman C.H., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl. J. Med. 2006, 354:899-910.
73. Rudick R.A., et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N. Engl. J. Med. 2006, 354:911-923.
74. Cohen J.A., et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012, 380:1819-1828.
75. Coles A.J., et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012, 380:1829-1839.
76. Vergunst C.E., et al. Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 2008, 58:1931-1939.
77. Carrieri P.B., et al. Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis: a correlation with clinical activity. Immunopharmacol. Immunotoxicol. 1998, 20:373-382.
78. Rasouli J., et al. Expression of GM-CSF in T Cells is increased in multiple sclerosis and suppressed by IFN-beta therapy. J. Immunol. 2015, 194:5085-5093.
79. Hamilton J.A. GM-CSF as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential. Expert Rev. Clin. Immunol. 2015, 11:457-465.
80. Hamilton J.A., Achuthan A. Colony stimulating factors and myeloid cell biology in health and disease. Trends Immunol. 2013, 34:81-89.
81. Burmester G.R., et al. Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-alpha, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study. Ann. Rheum. Dis. 2011, 70:1542-1549.
82. Behrens F., et al. MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. Ann. Rheum. Dis. 2015, 74:1058-1064.
83. Guilliams M., et al. Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF. J. Exp. Med. 2013, 210:1977-1992.
84. Miller A.L., et al. Clinical problem-solving. A crazy cause of dyspnea. N. Engl. J. Med. 2011, 364:72-77.
85. Shibata Y., et al. GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity 2001, 15:557-567.
86. Fogg D.K., et al. A clonogenic bone marrow progenitor specific for macrophages and dendritic cells. Science 2006, 311:83-87.
87. Hettinger J., et al. Origin of monocytes and macrophages in a committed progenitor. Nat. Immunol. 2013, 14:821-830.
88. Liu K., et al. In vivo analysis of dendritic cell development and homeostasis. Science 2009, 324:392-397.
89. Naik S.H., et al. Development of plasmacytoid and conventional dendritic cell subtypes from single precursor cells derived in vitro and in vivo. Nat. Immunol. 2007, 8:1217-1226.
90. Shortman K., Naik S.H. Steady-state and inflammatory dendritic-cell development. Nat. Rev. Immunol. 2007, 7:19-30.
91. Ginhoux F., Jung S. Monocytes and macrophages: developmental pathways and tissue homeostasis. Nat. Rev. Immunol. 2014, 14:392-404.
92. Serbina N.V., et al. TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection. Immunity 2003, 19:59-70.
93. Guilliams M., et al. Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. Nat. Rev. Immunol. 2014, 14:571-578.